

## Cyclical Neutropenia and Other Periodic Hematological Disorders: A Review of Mechanisms and Mathematical Models

By Caroline Haurie, David C. Dale, and Michael C. Mackey

Although all blood cells are derived from hematopoietic stem cells, the regulation of this production system is only partially understood. Negative feedback control mediated by erythropoietin and thrombopoietin regulates erythrocyte and platelet production, respectively, but the regulation of leukocyte levels is less well understood. The local regulatory mechanisms within the hematopoietic stem cells are also not well characterized at this point. Because of their dynamic character, cyclical neutropenia and other periodic hematological disorders offer a rare opportunity to more fully understand the nature of these regulatory processes. We review the salient clinical and laboratory features of cyclical neutro-

penia (and the less common disorders periodic chronic myelogenous leukemia, periodic auto-immune hemolytic anemia, polycythemia vera, aplastic anemia, and cyclical thrombocytopenia) and the insight into these diseases afforded by mathematical modeling. We argue that the available evidence indicates that the locus of the defect in most of these dynamic diseases is at the stem cell level (auto-immune hemolytic anemia and cyclical thrombocytopenia seem to be the exceptions). Abnormal responses to growth factors or accelerated cell loss through apoptosis may play an important role in the genesis of these disorders.

© 1998 by The American Society of Hematology.

### REGULATION OF HEMATOPOIESIS

**M**ATURE BLOOD CELLS and recognizable precursors in the bone marrow ultimately derive from a small population of morphologically undifferentiated cells, the hemopoietic stem cells (HSC), which have a high proliferative potential and sustain hematopoiesis throughout life (Fig 1). The earliest HSC are totipotent and have a high self-renewal capacity.<sup>1-3</sup> These qualities are progressively lost as the stem cells differentiate. Their progeny, the progenitor cells, or colony-forming units (CFUs), are committed to one cell lineage. They proliferate and mature to form large colonies of erythrocytes, granulocytes, monocytes, or megakaryocytes. The growth of CFUs in vitro depends on lineage-specific growth factors, such as erythropoietin (EPO), thrombopoietin (TPO), granulocyte colony-stimulating factor (G-CSF), monocyte colony-stimulating factor (M-CSF), and granulocyte-monocyte colony-stimulating factor (GM-CSF).

EPO adjusts erythropoiesis to the demand for O<sub>2</sub> in the body. A decrease in tissue pO<sub>2</sub> levels (in response to any one of a number of factors) leads to an increase in the renal production of EPO. This, in turn, leads to an increased cellular production by the primitive erythroid precursors (colony-forming units-erythroid [CFU-E]) and, ultimately, to an increase in the erythrocyte mass and hence the tissue pO<sub>2</sub> levels. This increased cellular production triggered by EPO is due, at least in part, to an inhibition of preprogrammed cell death (apoptosis)<sup>4,5</sup> in the CFU-E and their immediate progeny. Thus, EPO mediates a negative feedback such that an increase (decrease) in the erythrocyte mass leads to a decrease (increase) in erythrocyte production.

The mechanisms regulating granulopoiesis are not as well understood. G-CSF, the primary controlling agent of granulopoiesis, is a completely sequenced high molecular weight molecule<sup>6</sup> produced by a number of tissues (fibroblasts, endothelial, and epithelial) and circulating cells (monocytes). G-CSF is absolutely essential for the growth of the granulocytic progenitor cells colony-forming units-granulocyte (CFU-G) in vitro.<sup>7</sup> CFU-G colony growth is a sigmoidally increasing function of increasing G-CSF concentration.<sup>8,9</sup> One of the modes of action of G-CSF, along with several other cytokines, is to decrease

apoptosis.<sup>7,10-12</sup> Additionally, there is a clear shorting of the neutrophil maturation time under the action of G-CSF.<sup>13</sup>

The important role of G-CSF for the in vivo control of granulopoiesis was demonstrated by Lieschke et al.<sup>14</sup> They showed that mice lacking G-CSF (due to an ablation of the G-CSF gene in embryonal stem cells) have pronounced neutropenia and reduction of the marrow granulocyte precursor cells by a factor of 50%. The administration of exogenous G-CSF corrects the neutropenia in 1 day and restores the marrow composition to that typical of a normal wild-type mouse within 4 days. G-CSF also rapidly corrects neutropenia of diverse causes in humans<sup>15-20</sup> and other mammals.<sup>21-23</sup>

Several studies have shown an inverse relation between circulating neutrophil density and serum levels of G-CSF.<sup>24-27</sup> Coupled with the in vivo dependency of granulopoiesis on G-CSF, this inverse relationship suggests that the neutrophils would regulate their own production through a negative feedback, as is the case with erythrocytes, in which an increase (decrease) in the number of circulating neutrophils would induce a decrease (increase) in the production of neutrophils through the adjustment of G-CSF levels. Although mature neutrophils bear receptors for G-CSF and for GM-CSF, the role of these receptors in governing neutrophil production is not yet known.

The regulation of thrombopoiesis presumably involves similar negative feedback loops. Megakaryopoiesis can be separated

---

*From the Departments of Physiology, Physics, and Mathematics, Center for Nonlinear Dynamics in Physiology and Medicine, McGill University, Montreal, Quebec, Canada; and the Division of Hematology, Department of Medicine, University of Washington, Seattle, WA.*

*Submitted December 8, 1997; accepted June 25, 1998.*

*Supported by the Natural Sciences and Engineering Research Council (NSERC Grant No. OGP-0036920, Canada), the National Institutes of Health (NIH Grant No. 18951, USA), Le Fonds pour la Formation de Chercheurs et l'Aide à la Recherche (FCAR Grant No. 98ER1057, Québec), and the École Normale Supérieure de Paris.*

*Address reprint requests to Michael C. Mackey, PhD, Departments of Physiology, Physics, and Mathematics, Center for Nonlinear Dynamics in Physiology and Medicine, McGill University, McIntyre Drummond Building, 3655 Drummond St, Montreal H3G 1Y6, Quebec, Canada.*

*© 1998 by The American Society of Hematology.*

*0006-4971/98/9208-0034\$3.00/0*




Fig 1. The architecture and control of hematopoiesis. This figure gives a schematic representation of the architecture and control of platelet (P), red blood cell (RBC), and monocyte (M) and granulocyte (G) (including neutrophil, basophil, and eosinophil) production. Various presumptive control loops mediated by TPO, EPO, and G-CSF are indicated, as well as a local regulatory (LR) loop within the totipotent HSC population. CFU (BFU) refers to the various colony (burst) forming units (Meg, megakaryocyte; Mix, mixed; E, erythroid; G/M, granulocyte/monocyte) that are the *in vitro* analogs of the *in vivo* committed stem cells (CSC).

in two processes: the proliferation and differentiation of megakaryocytic progenitor cells, and the complex process of maturation of precursor cells, which includes a variable number of endomitotic nuclear divisions, cytoplasmic growth and maturation, and the development of platelet-specific structures.

Until recently, the regulation of megakaryopoiesis was thought to include two separated control mechanisms<sup>28,29</sup>: first, a regulatory loop mediated by a megakaryocyte colony stimulating antigen (Meg-CSA) responding to megakaryocyte demand and acting on the proliferation of colony-forming unit-megakaryocyte (CFU-Meg); second, a thrombocytopenia-activated control of the maturation of megakaryocytes, mediated by TPO. Several growth factors, such as interleukin-11 (IL-11), IL-6, IL-3, and GM-CSF possess either one (but not both) of these activities and promote platelet production *in vivo*. However, none was found to be specific to the megakaryocytic lineage.<sup>28</sup>

A lineage-specific factor that is the ligand for Mpl receptor has been cloned recently that has both Meg-CSA and TPO activity.<sup>30</sup> Plasma TPO levels are increased in thrombocytopenic patients.<sup>31</sup> Administration of TPO to nonhuman primates induces up to sixfold to sevenfold increases in the platelet counts.<sup>31,32</sup> It is now thought that the Mpl ligand mediates a negative feedback loop regulating platelet production.<sup>33</sup>

There are more than 15 other cytokines acting on hematopoiesis,<sup>6</sup> with broad, redundant actions.<sup>6,34</sup> *In vitro* studies have shown that IL-3 and stem cell factor (SCF; Kit ligand) are involved with the survival of HSC, whereas IL-6, IL-11, IL-12, and G-CSF have synergistic effects on the entry into cycling of dormant HSC.<sup>17,35</sup> In contrast to the committed progenitors, the growth of HSC *in vitro* thus depends on the interaction of several cytokines. The action of G-CSF on the cycling of HSC *in vitro* is supported by *in vivo* effects. Whereas suppression of G-CSF only affects granulopoiesis,<sup>14</sup> G-CSF administration can result in multilineage recovery<sup>36</sup> and modify the kinetics of colony-forming units-spleen (CFU-S).<sup>37</sup> Little is known about how the self-maintenance of the HSC population is achieved. HSC are usually in a dormant state but are triggered to

proliferate after transplantation into irradiated hosts.<sup>38</sup> The specific mechanisms regulating the differentiation commitment of HSC are unknown.<sup>39</sup> Self-maintenance of HSC depends on the balance between self-renewal and differentiation. Mechanisms that could support auto-regulatory feedback control loops controlling HSC kinetics are starting to be investigated.<sup>40</sup>

## PERIODIC HEMATOLOGICAL DISORDERS

### *Cyclical Neutropenia (CN)*

**General features.** CN has been the most extensively studied periodic hematological disorder. Its hallmark is a periodic decrease in the circulating neutrophil numbers from normal values to very low values. In humans, it occurs sporadically or as an autosomal dominantly inherited disorder, and the period is typically reported to fall in the range of 19 to 21 days,<sup>41</sup> although recent data indicate that longer periods occur in some patients.<sup>42</sup> Our understanding of CN has been greatly aided by the discovery that the grey collie suffers from a very similar disease. The canine disorder closely resembles human CN with the exception of the period that ranges from 11 to 15 days<sup>43</sup> and the maximum neutrophil counts, which are higher than for humans. For reviews see.<sup>41,44-50</sup>

It is now clear that in both human CN<sup>42,51-53</sup> and the grey collie,<sup>43,54</sup> there is not only a periodic decrease in the circulating neutrophil levels, but also a corresponding oscillation of platelets, often the monocytes and eosinophils and occasionally the reticulocytes and lymphocytes (Fig 2A). The monocyte, eosinophil, platelet, and reticulocyte oscillations are generally from normal to high levels, in contrast to the neutrophils, which oscillate from near normal to extremely low levels. Often (but not always), the period of the oscillation in these other cell lines is the same as the period in the neutrophils.

The clinical criteria for a diagnosis of CN have varied widely, although the criteria used by Dale et al<sup>58</sup> are widely accepted. These criteria are that a patient must display an absolute neutrophil count (ANC) less than  $0.5 \times 10^9/L$  at least 3 to 5




Fig 2. Representative patterns of circulating cell levels in four periodic hematological disorders considered in this review. (A) CN,<sup>54</sup> (B) PV,<sup>55</sup> (C) AA,<sup>56</sup> and (D) periodic CML.<sup>57</sup> The density scales are neutrophils,  $10^3$  cells/ $\mu$ L; white blood cells,  $10^4$  cells/ $\mu$ L; platelets,  $10^5$  cells/ $\mu$ L; reticulocytes,  $10^4$  cells/ $\mu$ L; and Hb, g/dL.

consecutive days per cycle for each of three regularly spaced cycles. Usually, this requires blood cell counts three times per week for 6 to 8 weeks. Most patients will also have significant symptoms (malaise and anorexia) and signs (eg, fever, mouth ulcers, and lymphadenopathy) during their neutropenic periods. Sometimes it is difficult to make the diagnosis with certainty. Using periodogram analysis, some patients classified as having CN do not in fact display any significant periodicity, whereas other patients classified with either congenital or idiopathic neutropenia do display significant cycling.<sup>42</sup>

*Origin.* Transplantation studies show that the origin of the defect in CN is resident in one of the stem cell populations of the bone marrow.<sup>59-64</sup> Studies of bone marrow cellularity throughout a complete cycle in humans with CN show that there is an orderly cell density wave that proceeds successively through the myeloblasts, promyelocytes, and myelocytes and then enters the maturation compartment before being manifested in the circulation.<sup>54,65</sup> Further studies have shown that this wave extends back into the CFU-G,<sup>66</sup> CFU-E,<sup>67-70</sup> as well as in the burst-forming unit-erythroid (BFU-E) and colony-forming unit-granulocyte-macrophage (CFU-GM),<sup>69,71</sup> suggesting that it may originate in the totipotent HSC populations.

Studies in the grey collie<sup>9,72</sup> and in humans<sup>8,73</sup> show that the responsiveness of granulocyte committed progenitor cells to G-CSF is greatly attenuated in CN compared with normal. Patients also differ from normal in their requirements for GM-CSF but not for IL-3.<sup>73</sup>

In CN, the levels of colony-stimulating activity (CSA-related to G-CSF) fluctuate inversely with the circulating neutrophil levels and in phase with the peak in monocyte numbers.<sup>74-76</sup> EPO levels oscillate approximately in phase with the reticulocyte oscillation.<sup>75</sup> Dunn et al<sup>77</sup> have also shown a periodic stimulation/repression of CFU-S (the HSC) by conditioned media derived from cyclic neutropenic marrow. It is unclear if these correlations and inverse correlations between levels of circulating cells and putative humoral regulators are related to the cause of CN or are simply a secondary manifestation of some other defect.

*Effect of phlebotomy and hypertransfusion.* The effect of bleeding and/or hypertransfusion on the hematological status of grey collies gives interesting results.<sup>78</sup> In the untreated grey collie, EPO levels cycle out of phase with the reticulocytes and virtually in phase with the neutrophil counts. After phlebotomy (bleeding of between 10% and 20% of the blood volume), the

cycles in the neutrophils and reticulocytes continue as they had before the procedure, and there is no change in the relative phase between the cycles of the two cell types. Hypertransfusion (with homologous red blood cells) completely eliminates the reticulocyte cycling (as long as the hematocrit level remained elevated), but has no discernible effect on the neutrophil cycle. Most significantly, when the hematocrit level decreases back to normal levels and the reticulocyte cycle returns, the phase relation between the neutrophils and the reticulocytes is the same as before the hypertransfusion. These observations suggest that the source of the oscillations in CN is relatively insensitive to any feedback regulators involved in peripheral neutrophil and erythrocyte control, whose levels would be modified with the alteration of the density of circulating cells, and is consistent with a relatively autonomous oscillation in the HSC (see "Models of the Autoregulatory Control of HSC" below).

*Effect of cytokine and lithium therapy.* In both the grey collie<sup>72,79</sup> and in humans with CN,<sup>80-82</sup> administration of G-CSF leads to an increase in the mean value of the peripheral neutrophil counts by a factor of as much as 10 to 20 and is associated with a clear improvement of the clinical symptoms. However, G-CSF does not obliterate the cycling in humans, but rather induces an increase in the amplitude of the oscillations and a decrease in the period of the oscillations in all the cell lineages, from 21 to 14 days.<sup>80</sup> In human and canine CN, GM-CSF leads to an increase in neutrophil count by a factor of between 1.5 and 3.5, which is much less than achieved by G-CSF. In one report, CM-CSF obliterated cycling.<sup>82</sup> Although recombinant canine stem cell factor (rc-SCF) does not cause neutrophilia in grey collies, it does obliterate the oscillations of CN. Lithium therapy in grey collies<sup>69,83</sup> has uniformly yielded an elimination of the severe neutropenic phases and a diminution in the amplitude of the oscillations without any apparent change in the period of the oscillation. In humans, there are variable results with lithium,<sup>84,85</sup> and the largest study showed lack of efficacy and toxicity problems.<sup>86</sup>

#### *Other Periodic Hematological Disorders Associated With Bone Marrow Defects*

*Periodic chronic myelogenous leukemia (CML).* CML is a hematopoietic stem cell disease characterized by granulocytosis and splenomegaly.<sup>87</sup> In 90% of the cases, the hematopoietic cells contain a translocation between chromosomes 9 and 22 that leads to the shortening of chromosome 22, referred to as the Philadelphia (Ph) chromosome. The disease is acquired and results from the malignant transformation of a single pluripotential stem cell, as shown by the presence of a single G-6PD isoenzyme in the red blood cells, neutrophils, eosinophils, basophils, monocytes, and platelets in women with CML who are heterozygotes for isoenzymes A and B.<sup>88</sup> The leukocyte count is greater than  $100 \times 10^9/L$  in 50% of the cases and it increases progressively in untreated patients. The platelet and reticulocyte counts can also be mildly elevated. In most cases, the disease eventually develops into acute leukemia.

Morley et al<sup>89</sup> was the first to describe oscillations in the leukocyte count of CML patients in 1967. Several other cases of cyclic leukocytosis in CML have now been reported.<sup>57,90-104</sup> The leukocyte count usually cycles with an amplitude of 30 to

$200 \times 10^9$  cells/L and with periods ranging from approximately 30 to 100 days. Oscillations of other blood elements in association with CML have been observed. The platelets and sometimes the reticulocytes then oscillate with the same period as the leukocytes, around normal or elevated numbers. There have been no specific studies of hematopoiesis in patients with periodic CML. There is also a report of one patient with periodic acute myelogenous leukemia.<sup>97</sup>

*Polycythemia vera (PV) and aplastic anemia (AA).* PV is characterized by an increased and uncontrolled proliferation of all the hematopoietic progenitors and it involves, like CML, the transformation of a single pluripotential stem cell. Two patients with PV were reported with cycling of the reticulocyte, platelet, and neutrophil counts in one case (Fig 2B) and cycling only of the reticulocyte counts in the other. The period of the oscillations was 27 days in the platelets, 15 days in the neutrophils, and 17 days in the reticulocytes.<sup>55</sup>

Finally, clear oscillations in the platelet, reticulocyte, and neutrophil counts (Fig 2C) were reported in a patient diagnosed as having AA<sup>56</sup> and in a patient with pancytopenia,<sup>105</sup> with periods of 40 and 100 days, respectively.

*Cytokine-induced cycling.* G-CSF is routinely used in a variety of clinical settings, eg, to treat chronic neutropenia or to accelerate recovery from bone marrow transplant and/or chemotherapy.<sup>58</sup> G-CSF may induce oscillations in the level of circulating neutrophils of neutropenic individuals.<sup>42,106-108</sup> When these oscillations arise, they always seem to be of relatively low period (on the order of 7 to 15 days), and their origin is unclear. There has also been one report of GM-CSF-induced 40-day cycling in a patient with CML after bone marrow transplant.<sup>109</sup>

*Induction of cycling by chemotherapy or radiation.* Several reports describe induction of a CN-like condition by the chemotherapeutic agent cyclophosphamide. In mongrel dogs on cyclophosphamide, the observed period was on the order of 11 to 17 days, depending on the dose of cyclophosphamide.<sup>110,111</sup> In a human undergoing cyclophosphamide treatment, cycling with a period of 5.7 days was reported.<sup>112</sup> Gidáli et al<sup>113</sup> observed oscillations in the granulocyte count and the reticulocyte counts with 3 weeks periodicity in mice after mild irradiation. They observed an overshooting regeneration in the reticulocytes and the thrombocytes but not in the granulocytes. Whereas the CFU-S returned to normal levels rapidly, the proliferation rate of CFU-S stayed abnormally elevated.

Five CML patients receiving hydroxyurea showed oscillations in their neutrophils, monocytes, platelets, and reticulocytes with periods in the range of 30 to 50 days.<sup>95</sup> In one patient, an increase of the hydroxyurea dose led to a cessation of the oscillations. Chikkappa et al<sup>114</sup> report a CN-like condition (period between 15 and 25 days) in a patient with multiple myeloma after 3 years of chemotherapy.

A <sup>89</sup>Sr-induced cyclic erythropoiesis has been described in two congenitally anemic strains of mice, W/W<sup>v</sup> and S1/S1<sup>d</sup>.<sup>115-117</sup> W/W<sup>v</sup> mice suffer from a defect in the HSC, and in S1/S1<sup>d</sup> mice the hematopoietic micro-environment is defective.

The induction of cycling by <sup>89</sup>Sr can be understood as a response to elevated cell death (see "Models of the Autoregulatory Control of HSC" below), as can the dynamic effects of chemotherapy.

*Periodic Hematological Disorders of Peripheral Origin: Auto-Immune Hemolytic Anemia (AIHA) and Cyclical Thrombocytopenia*

Periodic AIHA is a rare form of hemolytic anemia in humans.<sup>118</sup> Periodic AIHA, with a period of 16 to 17 days in hemoglobin and reticulocyte counts, has been induced in rabbits by using red blood cell auto-antibodies.<sup>119</sup>

Cyclic thrombocytopenia, in which platelet counts oscillate from normal to very low values, has been observed with periods between 20 and 40 days<sup>120-136</sup> (reviewed by Cohen and Cooney<sup>126</sup>). Although it has been claimed that oscillations could be detected in the platelet counts of normal individuals with the same range of periods,<sup>137,138</sup> this conclusion may not be statistically justified.

#### HYPOTHESES FOR THE ORIGIN OF PERIODIC HEMATOPOIESIS

In clinical reports of periodic diseases affecting hematopoiesis, oscillations have usually been observed only in the blood counts without examinations of bone marrow precursors and progenitor cells. However, even in the case of CN in which the kinetics of hematopoiesis have been extensively studied, the mechanisms responsible for the onset of periodic oscillations are still unknown. A number of mathematical models have been put forward that suggest possible mechanisms for the origin of oscillations in hematopoiesis. These models fall into two major categories. The first group identifies the origin of the oscillations with the loss of stability in peripheral control loops adjusting the production rate of blood precursors to the number of mature cells in the blood and mediated by TPO, EPO, and G-CSF (Fig 1). The second group is based on the assumption that oscillations arise in stem cell populations as a consequence of the loss of stability of auto-regulatory (local and LR) control loops (Fig 1). A few investigators have also modeled interactions between these two types of control loops (see Dunn<sup>139</sup> and Fisher<sup>140</sup> for reviews).

#### *Models of the Peripheral Control of Hematopoiesis*

It is well known that simple negative feedback systems, such as the erythroid control system, have a tendency to oscillate. The relative detail known about erythrocyte production control has not escaped the attention of modelers who have mathematically explored ways to explain the results of laboratory manipulations in rodents,<sup>141-147</sup> and rabbits<sup>119,148</sup> and the nature of the human erythropoietic regulatory system in health and disease.<sup>149-152</sup>

The control of erythropoiesis by EPO can be modeled by a single delayed differential equation describing the rate of change of RBC production as a function of the death rate of circulating erythrocytes, the rate of change of cell production after a given perturbation of the circulating RBC number, and the maturation time of erythrocyte progenitors. The transition from damped to stable oscillations, which characterizes the onset of periodic hematopoiesis, depends on the modification of one or several of these controlling parameters. In AIHA, the death rate of circulating RBC is increased, whereas the other parameters lie within normal ranges. The mathematical modeling of the control of RBC production by EPO indicates that such

an increase in the destruction rate of circulating erythrocytes will induce periodic fluctuations of erythropoiesis around a low average, with periods similar to the ones observed in AIHA.<sup>153-155</sup> From a modeling perspective, the laboratory version of rabbit AIHA is thus one of the best understood periodic hematological diseases.

Similar mathematical treatments have been applied to the control of granulopoiesis and megakaryopoiesis, even though the existence of functional peripheral feedback in these systems is still hypothetical.

A few investigators have formulated models for the regulation of thrombopoiesis<sup>138,156-159</sup> assuming the existence of a negative feedback loop mediated by TPO. Bélair and Mackey<sup>160</sup> specifically considered cyclical thrombocytopenia. They speculated that elevations in the random destruction rate of platelets could give rise to the characteristic patterns observed in cyclical thrombocytopenia. Although modeling results based on this assumption yielded results qualitatively consistent with the clinical data, there is still much room for further study of this problem.

Several models of granulopoiesis incorporate a peripheral negative feedback loop.<sup>161-172</sup> In the grey collie and in CN patients, the survival of circulating neutrophils is normal.<sup>51</sup> This finding implies that there is not a periodic elevation of the peripheral death rate of neutrophils in CN, but rather a periodic modulation of marrow cell production. An alteration of the peripheral control of granulopoiesis has been proposed as the mechanism of CN by several investigators.<sup>56,110,111,173-185</sup>

There is experimental evidence of alterations in the kinetics of granulopoiesis in CN, ie, the modification of the distribution of maturation time and the subnormal responsiveness of granulocytic progenitors to CSF. However, recent modeling indicates that these are insufficient to account for a destabilization of the putative peripheral feedback control of granulocytopenia.<sup>186</sup> Moreover, the lack of effect of hypertransfusion or phlebotomy on either cycle (neutrophil or reticulocyte) strongly implies that there is not a direct role of peripheral feedback loops in the origin of the cycling in CN.

A few attempts have also been made to model periodic CML based on the peripheral control of granulopoiesis<sup>171,187,188</sup> but are also unsatisfactory in the sense that the models have assumptions on the kinetic of granulopoiesis in CML that are now known to be biologically unrealistic.<sup>189,190</sup>

The occurrence of oscillations in several blood elements in CN and CML strongly suggests that the oscillations are not a consequence of a lineage-specific regulatory loop but rather of regulatory mechanisms affecting all hematopoiesis. The existence of a peripheral feedback loop controlling granulopoiesis can thus not be supported by the occurrence of oscillations in CN and CML.

#### *Models of the Autoregulatory Control of HSC*

Except for AIHA and cyclical thrombocytopenia, the periodic hematological disorders that have been described are characterized by the occurrence of oscillations in many or all of the peripheral cellular elements (neutrophils, platelets, lymphocytes, and reticulocytes). Many have speculated that the origin of these oscillations is in the common HSC population feeding progeny into the differentiated cell lines.

Mackey<sup>191,193</sup> proposed that there could be a loss of stability in the stem cell population independent of feedback from peripheral circulating cell types. He analyzed a mathematical model for a stem cell population in which the proportion of cells entering proliferation depends on the size of the population in  $G_0$  (Fig 3). The efflux into the different committed cell lineages depends on the size of the population, which varies with the rate of proliferation and the cell death rate.

Other investigators<sup>194-202</sup> have considered the dynamics of auto-regulatory stem cell populations from a modeling perspective applied to various experimental and clinical situations. Nečas et al<sup>40,203-205</sup> have developed such a modeling study based on experimental evidence that the number of stem cells entering proliferation is controlled by the number of DNA-synthesizing cells. Cell to cell interactions or cytokines that are essential for the growth of HSC in vitro, such as IL-3 and SCF, could be involved in the autoregulation of HSC proliferation.

Because of the delay in the autoregulation loop, due to the time necessary for replicating cells to go through the S phase and the mitotic phase, this system has a tendency to oscillate. In normal conditions it is assumed that the population does not oscillate. Mackey<sup>191</sup> showed that an abnormally large irreversible cell loss within the proliferating compartment, which can represent either apoptosis or other cell death, would induce oscillations of the number of stem cells. Figure 4 shows the variations in the amplitude and the period of the oscillations predicted by the model as the apoptotic rate is increased. An increase in the apoptotic rate of HSC also induces a decrease in the average efflux from the HSC to all the cell lineages. This is consistent with the occurrence of oscillations in all the blood elements in some patients with AA, in which all the blood cell counts are low, as well as the oscillations observed in several cell lineages after chemotherapy or radiation. The range of periods obtained by Mackey depends largely on the rate of irreversible cell loss and on the cell cycle time delay. Depending on the value of these parameters, the period can vary from 16 to

43 days in humans and from 9 to 26 days in dogs. In most periodic hematological disorders, large differences consistent with these values have been observed in the period of the oscillations between different individuals.

The model also gives a plausible explanation for the <sup>89</sup>Sr induction of cyclic erythropoiesis in the two congenitally anemic strains of mice,  $W/W^v$  and  $S1/S1^d$  (Fig 4). Assume that the difference between  $W/W^v$  and  $S1/S1^d$  mice is solely related to differences in the rate of apoptosis.<sup>206</sup> (The observation that  $S1/S1^d$  mice are more refractory to erythropoietin than  $W/W^v$  mice suggests that the apoptotic rate is higher in  $S1/S1^d$ .) The results of Mackey<sup>191</sup> predict that a higher rate of apoptosis would increase the likelihood that an oscillation in erythrocyte number occurs. Indeed, in contrast to  $W/W^v$  mice, approximately 40% of  $S1/S1^d$  mice have spontaneous oscillations in their hematocrit.<sup>115,116</sup> In both strains of mice, a single dose of <sup>89</sup>Sr is sufficient to increase apoptosis into a range associated with oscillations in erythrocyte number. Because the apoptotic rate for the  $S1/S1^d$  mice is greater than that for  $W/W^v$  mice before <sup>89</sup>Sr, it is reasonable to expect that it will also be higher after administration of equal doses of <sup>89</sup>Sr to both strains of mice. As predicted, the period of the oscillation is longer, the amplitude is larger, and the mean hematocrit is lower for  $S1/S1^d$  mice than they are for  $W/W^v$  mice.<sup>192</sup>

#### The Particular Cases of CN and CML

Destabilization of an early HSC population resulting in oscillations with a large range of periods in all the blood elements after radiation or chemotherapy and in AA may also be at the origin of the oscillations observed in CN and CML. Modification of any of the parameters in the model described in Mackey<sup>191</sup> (Fig 3) can potentially induce the onset of oscillations.

Even though all the blood elements are often oscillating in periodic CML and CN, the defect in these two disorders primarily affects granulopoiesis. The abnormal responsiveness





Fig 3. A schematic representation of the control of HSC regeneration. Proliferating phase cells include those cells in  $G_1$ , S (DNA synthesis),  $G_2$ , and M (mitosis), whereas the resting phase cells are in the  $G_0$  phase. Local regulatory influences are exerted via a cell number dependent variation in the rate of entry into proliferation. Differentiation into all of the committed stem cell populations occurs from the  $G_0$  population, whereas there is a loss of proliferating phase cells due to apoptosis. See Mackey<sup>191</sup> and Milton and Mackey<sup>192</sup> for further details.

**Fig 4. (A)** Schematic representation of the effects of increasing apoptotic rate on the HSC dynamics, as predicted from the model proposed previously.<sup>191,192</sup> The diagram shows the effect of administering the same dose of <sup>89</sup>Sr to W/W<sup>v</sup> and S1/S1<sup>d</sup> mice on the amplitude and the period of the oscillations. The dashed lines show the onset and the end of oscillations as the apoptotic rate increases. **(B)** Computer simulations of the normalized HSC efflux predicted<sup>191</sup> for increasing apoptotic rates (from I to V). As the apoptotic rate is increased, the period of the oscillations increases and the amplitude increases and decreases consecutively.



of CFU-G explains the low ANC levels in CN, which may induce an alteration in the cytokine levels. The fact that G-CSF is the only cytokine shown to alter the period of the oscillations in all the blood elements shows that it plays a crucial role in the mechanism at the origin of the oscillations in CN. The finding that G-CSF not only regulates granulopoiesis, but also affects the kinetics of early HSC suggests that its effect on the oscillations in CN may be mediated through the modification of HSC dynamics. In vitro studies of the effect of G-CSF suggest that it increases the rate of entry into cycling, which is likely to destabilize the steady state while increasing the average size of the population. This is consistent with the mildly elevated platelet, monocyte, and lymphocyte counts often observed in CN. Similar mechanisms may also induce the oscillations in CML.

The mechanisms underlying the complex dynamical features of CN and periodic CML will more likely be understood with the use of models that include both the local autoregulation of early stem cells and its relation with the more mature hemopoietic compartments. The multilevel effect of cytokines such as G-CSF suggests indeed that strong relationships exist between the regulation of early and late hematopoietic compartments.

**CONCLUSION**

This review focuses on the clinical and laboratory findings in periodic hematopoietic diseases, including CN, periodic CML, AA, PV, AIHA, and cyclical thrombocytopenia. With the exception of the latter two, the available evidence indicates a broad involvement of the entire hematopoietic system, because cycling is typically observed in more than one of the mature hematopoietic cell types.

Cycling in one or several hematopoietic cell lineages is

probably much more frequent than reported and would be detected if serial blood counts were systematically performed. These observations suggest a major derangement of the dynamics of one or more of the stem cell populations such that they become unstable and generate sustained oscillations that are manifested in more than one of their progenitor lines. Mathematical modeling studies suggest that there are several ways in which the HSC dynamics can be destabilized and give rise to oscillations if they are controlled by an autoregulatory loop. The finding that lineage-specific cytokines also have an effect on early HSC regulation implies that oscillations could arise as a result of the alteration of only one compartment, such as observed in CN and CML. Analysis of the effect of the cytokines on the dynamical features of these disorders, through modeling studies, may be a key to the understanding of the nature of early hematopoiesis regulation.

**REFERENCES**

1. Abramson S, Miller RG, Phillips RA: The identification in adult bone marrow of pluripotent and restricted stem cells of the myeloid and lymphoid systems. *J Exp Med* 145:1567, 1977
2. Becker A, McCulloch E, Till J: Cytological demonstration of the clonal nature of splenic colonies derived from transplanted mouse marrow cells. *Nature* 197:452, 1963
3. Lemishka IR, Raulet DH, Mulligan RC: Developmental potential and dynamic behavior of hemopoietic stem cells. *Cell* 45:917, 1986
4. Adamson J: The relationship of erythropoietin and iron metabolism to red blood cell production in humans. *Semin Oncol* 21:9, 1974
5. Silva M, Grillot D, Benito A, Richard C, Nunez G, Fernandez-Luna JL: Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through bcl-1 and bcl-2. *Blood* 88:1576, 1996
6. Metcalf D, Nicola NA: *The Hemopoietic Colony Stimulating Factors*. Cambridge, UK, Cambridge, 1995

7. Williams GT, Smith CA, Spooncer E, Dexter TM, Taylor DR: Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. *Nature* 353:76, 1990
8. Hammond WP, Chatta GS, Andrews RG, Dale DC: Abnormal responsiveness of granulocyte committed progenitor cells in cyclic neutropenia. *Blood* 79:2536, 1992
9. Avalos BR, Broudy VC, Ceselski SK, Druker BJ, Griffin JD, Hammond WP: Abnormal response to granulocyte colony stimulating factor (G-CSF) in canine cyclic hematopoiesis is not caused by altered G-CSF receptor expression. *Blood* 84:789, 1994
10. Koury MJ: Programmed cell death (apoptosis) in hematopoiesis. *Exp Hematol* 20:391, 1992
11. Park JR: Cytokine regulation of apoptosis in hematopoietic precursor cells. *Curr Opin Hematol* 3:191, 1996
12. Williams GT, Smith CA: Molecular regulation of apoptosis: Genetic controls on cell death. *Cell* 74:777, 1993
13. Price TH, Chatta GS, Dale DC: Effect of recombinant granulocyte colony stimulating factor on neutrophil kinetics in normal young and elderly humans. *Blood* 88:335, 1996
14. Lieschke GJ, Graill D, Hodgson G, Metcalf D, Stanley E, Cheers C, Fowler KJ, Basu S, Zhan YF, Dunn AR: Mice lacking granulocyte colony stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. *Blood* 84:1737, 1994
15. Bronchud MH, Scarffe JH, Thatcher N, Crowther D, Souza LM, Alton NK, Testa NG, Dexter TM: Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. *Br J Cancer* 56:809, 1987
16. Layton JE, Hockman H, Sheridan WP, Morstyn G: Evidence for a novel *in vivo* control mechanism of granulopoiesis: Mature cell-related control of a regulatory growth factor. *Blood* 74:1303, 1989
17. Leary AG, Zeng HQ, Clark SC, Ogawa M: Growth factor requirements for survival in  $G_0$  and entry into the cell cycle of primitive human hemopoietic progenitors. *Proc Natl Acad Sci USA* 89:4013, 1992
18. Lord BI: Myeloid cell kinetics in response to haemopoietic growth factors. *Clin Haematol* 5:533, 1992
19. Lord BI, Bronchud MH, Owens S, Chang J, Howell A, Souza L, Dexter TM: The kinetics of human granulopoiesis following treatment with granulocyte colony stimulating factor *in vivo*. *Proc Natl Acad Sci USA* 86:9499, 1989
20. Ponchio L, Conneally E, Eaves C: Quantitation of the quiescent fraction of long term culture initiating cells in normal human blood and marrow and the kinetics of their growth factor stimulated entry into *s* phase *in vitro*. *Blood* 86:3314, 1995
21. Cohen AM, Zsebo KM, Inoue H, Hines D, Boone TC, Chazin VR, Tsai L, Ritch T, Souza LM: *In vivo* stimulation of granulopoiesis by recombinant human granulocyte colony stimulating factor. *Proc Natl Acad Sci USA* 84:2484, 1987
22. Lord BI, Molineux G, Pojda Z, Souza LM, Mermod JJ, Dexter TM: Myeloid cell kinetics in mice treated with recombinant interleukin-3, granulocyte colony-stimulating factor (CSF), or granulocyte-macrophage CSF *in vivo*. *Blood* 77:2154, 1991
23. Molineux G, Pojda Z, Dexter TM: A comparison of hematopoiesis in normal and splenectomized mice treated with granulocyte colony stimulating factor. *Blood* 75:563, 1990
24. Kearns CM, Wang WC, Stute N, Ihle JN, Evans WE: Disposition of recombinant human granulocyte colony stimulating factor in children with severe chronic neutropenia. *J Pediatr* 123:471, 1993
25. Mempel K, Pietsch T, Menzel T, Zeidler C, Welte K: Increased serum levels of granulocyte colony stimulating factor in patients with severe congenital neutropenia. *Blood* 77:1919, 1991
26. Takatani H, Soda H, Fukuda M, Watanabe M, Kinoshita A, Nakamura T, Oka M: Levels of recombinant human granulocyte colony stimulating factor in serum are inversely correlated with circulating neutrophil counts. *Antimicrob Agents Chemother* 40:988, 1996
27. Watari K, Asano S, Shirafuji N, Kodo H, Ozawa K, Takaku F, Kamachi S: Serum granulocyte colony stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay. *Blood* 73:117, 1989
28. Hoffman R: Regulation of megakaryocytopoiesis. *Blood* 74:1196, 1989
29. Mazur EM: Megakaryocytopoiesis and platelet production: A review. *Exp Hematol* 15:340, 1987
30. Wendling F, Maraskovski E, Debill N, Florinda C, Teepe M, Titeux M, Methia N, Breton-Gorius J, Cosman D, Vainchenker W: c-mpl ligand is a humoral regulator of megakaryopoiesis. *Nature* 369:571, 1994
31. Nichol JL, Hokom MM, Hornkohl A, Sheridan WP, Ohashi H, Kato T, Li YS, Bartley TD, Choi E, Bogenberger J: Megakaryocyte growth and development factor: Analyses of *in vitro* effects on human megakaryopoiesis and endogenous serum levels during chemotherapy induced thrombocytopenia. *J Clin Invest* 95:2973, 1995
32. Kaushansky K: Thrombopoietin: The primary regulator of platelet production. *Blood* 86:419, 1995
33. Sheridan WP, Kuter DJ: Mechanism of action and clinical trials of mpl ligand. *Curr Opin Hematol* 4:312, 1997
34. Sachs L, Lotem J: The network of hematopoietic cytokines. *Proc Soc Exp Biol Med* 206:170, 1994
35. Ogawa M: Hematopoiesis. *J Allergy Clin Immunol* 94:645, 1994
36. Sonoda Y, Yashige H, Fujii H, Tsuda S, Maekawa T, Misawa S, Abe T: Bilineage response in refractory aplastic anemia patients following long-term administration of recombinant human granulocyte colony-stimulating factor. *Eur J Haematol* 48:41, 1992
37. Mizoguchi H, Suda T, Miura Y, Kubota K, Takahashi F: Hemopoietic stem cells in nude mice transplanted with colony-stimulating-factor-producing tumors. *Exp Hematol* 10:874, 1982
38. Necas E: Triggering of stem cell (cfu-s) proliferation after transplantation into irradiated hosts. *Exp Hematol* 20:1146, 1992
39. Ogawa M: Differentiation and proliferation of hematopoietic stem cells. *Blood* 81:2844, 1993
40. Necas E, Znojil V, Vacha J: Stem cell number versus the fraction synthesizing dna. *Exp Hematol* 16:231, 1988
41. Dale DC, Hammond WP: Cyclic neutropenia: A clinical review. *Blood Rev* 2:178, 1988
42. Haurie C, Mackey MC, Dale DC: Dynamics in congenital, idiopathic, and cyclical neutropenia before and after treatment with G-CSF. *Exp Hematol* (in press)
43. Haurie C, Person R, Mackey MC, Dale DC: Neutrophil dynamics in the grey collie: Modification of cyclical neutropenia by G-CSF. (manuscript in preparation)
44. Dale DC, Wolff SM: Cyclic neutropenia in man and gray collie dogs. *Birth Defects* 8:59, 1972
45. Jones JB, Lange RD: Cyclic hematopoiesis: Animal models. *Immunol Hematol Res Monogr* 1:33, 1983
46. Lange RD: Cyclic hematopoiesis: Human cyclic neutropenia. *Exp Hematol* 11:435, 1983
47. Lange RD, Jones JB: Cyclic hematopoiesis: Animal models. *Exp Hematol* 11:571, 1983
48. Page AR, Good RA: Studies on cyclic neutropenia. *Am J Dis Child* 94:623, 1957
49. Quesenberry PJ: Cyclic hematopoiesis: Disorders of primitive hematopoietic stem cells. *Immunol Hematol Res Monogr* 1:2, 1983
50. Wright DG, Dale DC, Fauci AS, Wolff SM: Human cyclic neutropenia: Clinical review and long term follow up of patients. *Medicine* 60:1, 1981
51. Dale DC, Ward SB, Kimball JR, Wolff SM: Studies of neutrophil production and turnover in grey collie dogs with cyclic neutropenia. *J Clin Invest* 51:2190, 1972



52. Dale DC, Alling DW, Wolff SW: Cyclic hematopoiesis: The mechanism of cyclic neutropenia in grey collie dogs. *J Clin Invest* 51:2197, 1972
53. Hoffman HJ, Guerry D, Dale DC: Analysis of cyclic neutropenia using digital band-pass filtering techniques. *J Interdisciplinary Cycle Res* 5:1, 1974
54. Guerry D, Dale DC, Omine M, Perry S, Wolff SM: Periodic hematopoiesis in human cyclic neutropenia. *J Clin Invest* 52:3220, 1973
55. Morley A: Blood-cell cycles in polycythaemia vera. *Aust Ann Med* 18:124, 1969
56. Morley A: Cyclic hemopoiesis and feedback control. *Blood Cells* 5:283, 1979
57. Chikkappa G, Burlington H, Borner G, Chanana AD, Cronkite EP, Ohl S, Pavelec M, Robertso JS: Periodic oscillation of blood leukocytes, platelets, and reticulocytes in a patient with chronic myelocytic leukemia. *Blood* 47:1023, 1976
58. Dale DC, Bonilla MA, Davis MW, Nakanishi AM, Hammond WP, Kurtzberg J, Wang W, Jakubowski A, Winton E, Lalezari P, Robinson W, Glaspy JA, Emerson S, Gabrilove J, Vincent M, Boxer LA: A randomized controlled phase III trial of recombinant human granulocyte colony stimulating factor (filgrastim) for treatment of severe chronic neutropenia. *Blood* 81:2496, 1993
59. Dale DC, Graw RG: Transplantation of allogenic bone marrow in canine cyclic neutropenia. *Science* 183:83, 1974
60. Jones JB, Lange RD, Yang TJ, Vodopick H, Jones ES: Canine cyclic neutropenia: Erythropoietin and platelet cycles after bone marrow transplantation. *Blood* 45:213, 1975
61. Jones JB, Yang TJ, Dale JB, Lange RD: Canine cyclic haematopoiesis: Marrow transplantation between littermates. *Br J Haematol* 30:215, 1975
62. Weiden PL, Robinett B, Graham TC, Adamson J, Storb R: Canine cyclic neutropenia. *J Clin Invest* 53:950, 1974
63. Krance RA, Spruce WE, Forman SJ, Rosen RB, Hecht T, Hammond WP, Blume G: Human cyclic neutropenia transferred by allogeneic bone marrow grafting. *Blood* 60:1263, 1982
64. Patt HM, Lund JE, Maloney MA: Cyclic hematopoiesis in grey collie dogs: A stem-cell problem. *Blood* 42:873, 1973
65. Brandt L, Forssman O, Mitelman R, Odeberg H, Oloffson T, Olson I, Svensson B: Cell production and cell function in human cyclic neutropenia. *Scand J Haematol* 15:228, 1975
66. Jacobsen N, Broxmeyer HE: Oscillations of granulocytic and megakaryocytic progenitor cell populations in cyclic neutropenia in man. *Scand J Haematol* 23:33, 1979
67. Dunn CDR, Jones JB, Lange RD: Progenitor cells in canine cyclic hematopoiesis. *Blood* 50:1111, 1977
68. Dunn CDR, Jolly JD, Jones JB, Lange RD: Erythroid colony formation *in vitro* from the marrow of dogs with cyclic hematopoiesis: Interrelationship of progenitor cells. *Exp Hematol* 6:701, 1978
69. Hammond WP, Dale DC: Cyclic hematopoiesis: Effects of lithium on colony forming cells and colony stimulating activity in grey collie dogs. *Blood* 59:179, 1982
70. Jones JB, Jolly JD: Canine cyclic haematopoiesis: Bone marrow adherent cell influence of CFU-C formation. *Br J Haematol* 50:607, 1982
71. Abkowitz JL, Holly RD, Hammond WP: Cyclic hematopoiesis in dogs: Studies of erythroid burst forming cells confirm an early stem cell defect. *Exp Hematol* 16:941, 1988
72. Lothrop CD, Warren DJ, Souza LM, Jones JB, Moore MAS: Correction of canine cyclic hematopoiesis with recombinant human granulocyte colony-stimulating factor. *Blood* 72:1324, 1988
73. Wright DG, LaRussa VF, Salvado AJ, Knight RD: Abnormal responses of myeloid progenitor cells to granulocyte macrophage colony stimulating factor in human cyclic neutropenia. *J Clin Invest* 83:1414, 1989
74. Dale DD, Brown C, Carbone P, Wolff SM: Cyclic urinary leukopoietic activity in gray collie dogs. *Science* 173:152, 1971
75. Guerry D, Adamson DJW, Dale C, Wolff SM: Human cyclic neutropenia: Urinary colony-stimulating factor and erythropoietin levels. *Blood* 44:257, 1974
76. Moore M, Spitzer G, Metcalf D, Penington DG: Monocyte production of colony stimulating factor in familial cyclic neutropenia. *Br J Haematol* 27:47, 1974
77. Dunn CDR, Jones JB, Lange RD, Wright EG, Moore MAS: Production of presumptive humoral haematopoietic regulators in canine cyclic haematopoiesis. *Cell Tissue Kinet* 15:1, 1982
78. Adamson JW, Dale DC, Elin RJ: Hematopoiesis in the grey collie dog: Studies of the regulation of erythropoiesis. *J Clin Invest* 54:965, 1974
79. Hammond WP, Boone TC, Donahue RE, Souza LM, Dale DC: Comparison of treatment of canine cyclic hematopoiesis with recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), G-CSF, interleukin-3, and canine G-CSF. *Blood* 76:523, 1990
80. Hammond WP, Price TH, Souza LM, Dale DC: Treatment of cyclic neutropenia with granulocyte colony stimulating factor. *N Engl J Med* 320:1306, 1989
81. Migliaccio AR, Migliaccio G, Dale DC, Hammond WP: Hematopoietic progenitors in cyclic neutropenia: Effect of granulocyte colony stimulating factor *in vivo*. *Blood* 75:1951, 1990
82. Wright DG, Kenney RF, Oette DH, LaRussa VF, Boxer LA, Malech HL: Contrasting effects of recombinant human granulocyte-macrophage colony-stimulating factor (CSF) and granulocyte CSF treatment on the cycling of blood elements in childhood-onset cyclic neutropenia. *Blood* 84:1257, 1994
83. Hammond WP, Dale DC: Lithium therapy of canine cyclic hematopoiesis. *Blood* 55:26, 1980
84. Fehr J, von Schulthess GK, Dahinde C: Cyclic neutropenia: Amplification of granulocyte oscillations by lithium and long-term suppression of cycling by plasmapheresis. *Blood* 62:320, 1983
85. Verma DS, Spitzer G, Zander AR, Dicke KA, McCredie KB: Cyclic neutropenia and T lymphocyte suppression of granulopoiesis: Abrogation of the neutropenic cycles by lithium carbonat. *Leuk Res* 6:567, 1982
86. Hammond WP, Berman B, Wright DG, Dale DC: Lithium is an ineffective therapy for human cyclic hematopoiesis. *Blood* 61:1024, 1983
87. Grignani F: Chronic myelogenous leukemia. *Crit Rev Oncol Hematol* 4:31, 1985
88. Fialkow PJ, Jacobson RJ, Papayannopoulou T: Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. *Am J Med* 63:125, 1977
89. Morley AA, Baikie AG, Galton DAG: Cyclic leukocytosis as evidence for retention of normal homeostatic control in chronic granulocytic leukaemia. *Lancet* 2:1320, 1967
90. Delobel J, Charbord P, Passa P, Bernard J: Evolution cyclique spontanée de la leucocytose dans un cas de leucémie myéloïde chronique. *Nouv Rev Franc Hématol* 13:221, 1973
91. Gatti RA, Robinson WA, Deinare AS, Nesbit M, Ballow M, Good RA, McCullough JJ: Cyclic leukocytosis in chronic myelogenous leukemia. *Blood* 41:771, 1973
92. German HJ, Smith JA, Lindenbaum J: Chronic intravascular coagulation associated with chronic myelocytic leukemia. *Am J Med* 61:547, 1976
93. Iizuka Y, Horikoshi A, Sekiya S, Sawada U, Ohshima T, Amaki I: Periodic fluctuation of leukocytes, platelets and reticulocytes in a case of chronic myelocytic leukemia: The relation between leukocyte counts, CFU-C colony formation, CSA and CIA. *Acta Haematol Jpn* 47:71, 1984

94. Inbal A, Akstein E, Barok I, Meytes D, Many A: Cyclic leukocytosis and long survival in chronic myeloid leukemia. *Acta Haematol* 69:353, 1983
95. Kennedy BJ: Cyclic leukocyte oscillations in chronic myelogenous leukemia during hydroxyurea therapy. *Blood* 35:751, 1970
96. Mastrangelo R, Stabile A, Parenti D, Segni G: Spontaneous leukocyte oscillation during blastic crisis of chronic myeloid leukemia. *Cancer* 33:1610, 1974
97. Mastrangelo R, Stabile A, Parenti D, Cimatti G: A specific spontaneous leukocyte cycle in chronic myelogenous leukemia. *Tumori* 62:197, 1976
98. Meitra BC, Agarwa B: Cyclic oscillations in leukocyte count in chronic myeloid leukemia. *Acta Haematol* 63:68, 1980
99. Olofsson T, Olsson I: Granulopoiesis in chronic myeloid leukemia. II. Serial cloning of blood and bone marrow cells in agar culture. *Blood* 48:351, 1976
100. Rodriguez AR, Lutchter CL: Marked cyclic leukocytosis leukopenia in chronic myelogenous leukemia. *Am J Med* 60:1041, 1976
101. Shaddock RK, Winkelstein A, Nunna NG: Cyclic leukemia cell production in CML. *Cancer* 29:399, 1972
102. Umemura T, Hirata J, Kaneko S, Nishimura J, Motomura S, Kozuru M, Ibayashi H: Periodical appearance of erythropoietin-independent erythropoiesis in chronic myelogenous leukemia with cyclic oscillation. *Acta Haematol* 76:230, 1986
103. Vodopick H, Rupp EM, Edwards CL, Goswitt GA, Beauchamp JJ: Spontaneous cyclic leukocytosis and thrombocytosis in chronic granulocytic leukemia. *N Engl J Med* 286:284, 1972
104. Yamauchi K, Ide A: Spontaneous remission with cyclic leukocytosis in chronic myelogenous leukemia. *Acta Haematol* 88:136, 1992
105. Birgens HS, Karl H: Reversible adult-onset cyclic haematopoiesis with a cycle length of 100 days. *Br J Haematol* 83:181, 1993
106. Bonilla MA, Gillio AP, Kernan NA, Ruggeiro M, Brochstein JL, Abboud M, Fumagalli L, Vincent M, Gabrielove JL, Welte K, Souza LM, O'Reilly RJ: Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. *N Engl J Med* 320:1574, 1989
107. Jakubowski AA, Souza L, Kelly F, Fain K, Budman D, Moore MAS, Gabrielov J, Clarkson B, Bonilla MA: Effects of human granulocyte colony stimulating factor in a patient with idiopathic neutropenia. *N Engl J Med* 320:38, 1989
108. Welte K, Zeidler C, Reiter A, Muller W, Odenwald E, Souza L, Riehm H: Differential effects of granulocyte macrophage colony stimulating factor and granulocyte colony stimulating factor in children with severe congenital neutropenia. *Blood* 75:1056, 1990
109. Gluckman E, Socie AG, Yver A, Esperou H, Devergie A, Stern A: Transient cyclic neutropenia following GM-CSF in a patient with chronic granulocytic leukemia transplanted with HLA identical T cell depleted donor bone marrow. *Bone Marrow Transplant* 4:591, 1989
110. Morley A, King-Smith EA, Stohlman F: The oscillatory nature of hemopoiesis, Stohlman F (ed): *Hemopoietic Cellular Proliferation*. New York, NY, Grune & Stratton, 1969, p 3
111. Morley A, Stohlman F: Cyclophosphamide induced cyclical neutropenia. *N Engl J Med* 282:643, 1970
112. Dale DC, Alling DW, Wolff SM: Application of time series analysis to serial blood neutrophil counts in normal individuals and patients receiving cyclophosphamide. *Br J Haematol* 24:57, 1973
113. Gidáli J, István E, Fehér I: Long-term perturbation of hemopoiesis after moderate damage to stem cells. *Exp Hematol* 13:647, 1985
114. Chikkappa G, Chanana AD, Chandra P, Cronkite EP, Thompson KH: Cyclic oscillation of blood neutrophils in a patient with multiple myeloma. *Blood* 55:61, 1980
115. Gibson CM, Gurney CW, Gaston EO, Simmons EL: Cyclic erythropoiesis in the  $s1/s1^d$  mouse. *Exp Hematol* 12:343, 1984
116. Gibson CM, Gurney CW, Simmons EL, Gaston EO: Further studies on cyclic erythropoiesis in mice. *Exp Hematol* 13:855, 1985
117. Gurney CW, Simmons EL, Gaston EO: Cyclic erythropoiesis in w/w<sup>y</sup> mice following a single small dose of <sup>89</sup>Sr. *Exp Hematol* 9:118, 1981
118. Ranlov P, Videbaek A: Cyclic haemolytic anaemia synchronous with pel-ebstein fever in a case of Hodgkin's disease. *Acta Med Scand* 100:429, 1963
119. Orr JS, Kirk J, Gray KG, Anderson JR: A study of the interdependence of red cell and bone marrow stem cell populations. *Br J Haematol* 15:23, 1968
120. Aranda E, Dorantes S: Garcia's disease: Cyclic thrombocytopenic purpura in a child and abnormal platelet counts in his family. *Scand J Haematol* 18:39, 1977
121. Balduini C, Stella C, Rosti V, Bertolino G, Noris P, Ascari E: Acquired cyclic thrombocytopenia thrombocytosis with periodic defect of platelet function. *Br J Haematol* 85:718, 1993
122. Bernard J, Caen J: Purpura thrombopénique et megacaryocytopenie cycliques mensuels. *Nouv Rev Franc Hematol* 2:378, 1962
123. Brey O, Garner EPR, Wells D: Cyclic thrombocytopenia associated with multiple antibodies. *Br Med J* 3:397, 1969
124. Caen J, Meshaka G, Larrieu MJ, Bernard J: Les purpuras thrombopéniques intermittents idiopathiques. *Semin Hop Paris* 40:276, 1964
125. Chintagumpala MM, Hurwitz RL, Moake JL, Mahoney DH, Steuber CP: Chronic relapsing thrombotic thrombocytopenic purpura in infants with large von Willebrand factor multimers during remission. *J Pediatr* 120:49, 1992
126. Cohen T, Cooney DP: Cyclical thrombocytopenia: Case report and review of literature. *Scand J Haematol* 16:133, 1974
127. Dan K, Inokuchi K, An E, Nomura T: Cell mediated cyclic thrombocytopenia treated with azathioprine. *Br J Haematol* 77:365, 1991
128. Demmer T: Morbus maculosus werlhofii in regelmässigen vierwöchentlichen schubben bei einem 60 jährigen mann, nebst untersuchungen über die blutplättchen. *Folia Haematol* 26:74, 1920
129. Engstrom K, Lundquist A, Soderstrom N: Periodic thrombocytopenia or tidal platelet dysgenesis in a man. *Scand J Haematol* 3:290, 1966
130. Goldschmidt B, Fono R: Cyclic fluctuations in platelet count, megakaryocyte maturation and thrombopoietin activity in cyanotic congenital heart disease. *Acta Paediatr Scand* 61:310, 1972
131. Lewis ML: Cyclic thrombocytopenia: A thrombopoietin deficiency. *J Clin Pathol* 27:242, 1974
132. Skoog WA, Lawrence JS, Adams WS: A metabolic study of a patient with idiopathic cyclical thrombocytopenic purpura. *Blood* 12:844, 1957
133. Tefferi A, Solberg LA, Pettit RM, Willis LG: Adult onset cyclic bicytopenia: A case report and review of treatment of cyclic hematopoiesis. *Am J Hematol* 30:181, 1989
134. Wasastjerna C: Cyclic thrombocytopenia of acute type. *Scand J Haematol* 4:380, 1967
135. Wilkinson T, Firkin B: Idiopathic cyclical acute thrombocytopenic purpura. *Med J Aust* 1:217, 1966
136. Yanabu M, Nomura S, Fukuroi T, Kawakatsu T, Kido H, Yamaguchi K, Suzuki M, Kokawa T, Yasunaga K: Periodic production of antiplatelet autoantibody directed against GP IIIa in cyclic thrombocytopenia. *Acta Haematol* 89:155, 1993
137. Morley A: A platelet cycle in normal individuals. *Aust Ann Med* 18:127, 1969
138. von Schulthess GK, Gessner U: Oscillating platelet counts in healthy individuals: Experimental investigation and quantitative evaluation of thrombocytopenic feedback control. *Scand J Haematol* 36:473, 1986
139. Dunn CDR: Cyclic hematopoiesis: The biomathematics. *Exp Hematol* 11:779, 1983

140. Fisher GV: An introduction to chaos theory and some haematological applications. *Comp Haematol Int* 3:43, 1993
141. Hodgson G, Eskuche I: Aplicacion de la teoria de control al estudio de la eritropoyesis. *Arch Biol Med Exp* 3:85, 1966
142. Loeffler M, Pantel K: A mathematical model of erythropoiesis suggests an altered plasma volume control as cause for anemia in aged mice. *Exp Gerontol* 25:483, 1990
143. Loeffler M, Pantel K, Wulff H, Wichmann HE: A mathematical model of erythropoiesis in mice and rats. Part I: Structure of the model. *Cell Tissue Kinet* 22:13, 1989
144. Vácha J, Znojil V: Application of a mathematical model of erythropoiesis to the process of recovery after acute x-irradiation of mice. *Biofizika* 20:872, 1975
145. Wichmann HE, Loeffler M, Pantel K, Wulff H: A mathematical model of erythropoiesis in mice and rats. Part 2: Stimulated erythropoiesis. *Cell Tissue Kinet* 22:31, 1989
146. Wulf H, Wichmann HE, Pantel K, Loeffler M: A mathematical model of erythropoiesis in mice and rats. Part 3: Suppressed erythropoiesis. *Cell Tissue Kinet* 22:51, 1989
147. Znojil V, Vácha J: Mathematical model of the cytokinetics of erythropoiesis in the bone marrow and spleen of mice. *Biofizika* 20:661, 1975
148. Kirk J, Orr JS, Hop CS: A mathematical analysis of red blood cell and bone marrow stem cell control mechanism. *Br J Haematol* 15:35, 1968
149. Kretchmar AL: Erythropoietin: Hypothesis of action tested by analog computer. *Science* 152:367, 1966
150. Monot C, Najean Y, Dresch C, Martin J: Models of erythropoiesis and clinical diagnosis. *Math Biosci* 27:145, 1975
151. Mylrea KC, Albrecht PH: Mathematical analysis and digital simulation of the control of erythropoiesis. *J Theor Biol* 33:279, 1971
152. Wichmann HE, Spechtmeier H, Gerecke D, Gross R: A mathematical model of erythropoiesis in man. *Lecture Notes in Biomathematics* 11:159, 1976
153. Bélair J, Mackey M, Mahaffy JM: Age-structured and two-delay models for erythropoiesis. *Math Biosci* 128:317, 1995
154. Mackey MC: Periodic auto-immune hemolytic anemia: An induced dynamical disease. *Bull Math Biol* 41:829, 1979
155. Mahaffy JM, Bélair J, Mackey MC: Hematopoietic model with moving boundary condition and state dependent delay. *J Theor Biol* 190:135, 1998
156. Eller J, Gyori I, Zollei J, Krizsa F: Modelling thrombopoiesis regulation I: Model description and simulation results. *Comput Math Appl* 14:841, 1987
157. Gray WM, Kirk J: Analysis by analogue and digital computers of the bone marrow stem cell and platelet control mechanisms, in *Proceedings of Conference on Computers for Analysis and Control in Medical and Biological Research*. UK, IEE, 1971, p 120
158. Gyori I, Eller J: Modelling thrombopoiesis regulation II: Mathematical investigation of the model. *Comput Math Appl* 14:849, 1987
159. Wichmann HE, Gerhards MD, Spechtmeier H, Gross R: A mathematical model of thrombopoiesis in rat. *Cell Tissue Kinet* 12:551, 1979
160. Bélair J, Mackey M: A model for the regulation of mammalian platelet. *Ann NY Acad Sci* 504:280, 1987
161. Blumenson LE: A comprehensive modeling procedure for the human granulopoietic system: Over-all view and summary of data. *Blood* 42:303, 1973
162. Blumenson LE: A comprehensive modeling procedure for the human granulopoietic system: Detailed description and application to cancer chemotherapy. *Math Biosci* 26:217, 1975
163. Fokas AS, Keller JB, Clarkson BD: Mathematical model of granulocytopenia and chronic myelogenous leukemia. *Cancer Res* 51:2084, 1991
164. Rubinow SI: A simple model of a steady state differentiating cell system. *J Cell Biol* 43:32, 1969
165. Rubinow SI, Lebowitz JL, Sapse AM: Parameterization of *in vivo* leukemic cell populations. *Biophys J* 11:175, 1971
166. Rubinow SI, Lebowitz JL: A mathematical model of neutrophil production and control in normal man. *J Math Biol* 1:187, 1975
167. Rubinow SI, Lebowitz JL: A mathematical model of the acute myeloblastic leukemia. *Biophys J* 16:897, 1976
168. Rubinow SI, Lebowitz JL: A mathematical model of the chemotherapeutic treatment of acute myeloblastic leukemia. *Biophys J* 16:1257, 1976
169. Smeby W, Benestad HB: Simulation of murine granulopoiesis. *Blut* 41:47, 1980
170. Steinbach KH, Raffler H, Pabst G, Flidner TM: A mathematical model of canine granulocytopenia. *J Math Biol* 10:1, 1980
171. Wheldon TE: Mathematical models of oscillatory blood cell production. *Math Biosci* 24:289, 1975
172. Wichmann HE, Loeffler M: *Mathematical Modeling of Cell Proliferation: Stem Cell Regulation in Hemopoiesis*. Boca Raton, FL, CRC, 1988
173. Kazarinoff ND, van den Driessche P: Control of oscillations in hematopoiesis. *Science* 203:1348, 1979
174. King-Smith EA, Morley A: Computer simulation of granulopoiesis: Normal and impaired granulopoiesis. *Blood* 36:254, 1970
175. MacDonald N: Cyclical neutropenia: Models with two cell types and two time lags, in Valleron AJ, Macdonald PDM (eds): *Biomathematics and Cell Kinetics*. Amsterdam, The Netherlands, Elsevier/North-Holland, 1978, p 287
176. Morley A: Periodic diseases, physiological rhythms and feedback control—A hypothesis. *Aust Ann Med* 3:244, 1970
177. Reeve J: An analogue model of granulopoiesis for the analysis of isotopic and other data obtained in the non-steady state. *Br J Haematol* 25:15, 1973
178. von Schulthess GK, Mazer NA: Cyclical neutropenia (CN): A clue to the control of granulopoiesis. *Blood* 59:27, 1982
179. Shvitra D, Laugalys R, Kolesov YS: *Mathematical modeling of the production of white blood cells*, in Marchuk G, Belykh LN (eds): *Mathematical Modeling in Immunology and Medicine*. Amsterdam, The Netherlands, North-Holland, 1983, p 211
180. Schmitz S: *Ein mathematisches Modell der zyklischen Haemopoese*. PhD thesis, Koln, Germany, Universitat Koln, 1988
181. Schmitz S, Franke H, Brusis J, Wichmann HE: Quantification of the cell kinetic effects of G-CSF using a model of human granulopoiesis. *Exp Hematol* 21:755, 1993
182. Schmitz S, Franke H, Loeffler M, Wichmann HE, Diehl V: Reduced variance of bone-marrow transit time of granulopoiesis: A possible pathomechanism of human cyclic neutropenia. *Cell Prolif* 27:655, 1994
183. Schmitz S, Franke H, Wichmann HE, Diehl V: The effect of continuous G-CSF application in human cyclic neutropenia: A model analysis. *Br J Haematol* 90:41, 1995
184. Schmitz S, Loeffler M, Jones JB, Lange RD, Wichmann HE: Synchrony of bone marrow proliferation and maturation as the origin of cyclic haemopoiesis. *Cell Tissue Kinet* 23:425, 1990
185. Wichmann HE, Loeffler M, Schmitz S: A concept of hemopoietic regulation and its biomathematical realization. *Blood Cells* 14:411, 1988
186. Hearn T, Haurie C, Mackey MC: Cyclical neutropenia and the peripheral control of white blood cell production. *J Theor Biol* 192:167, 1998
187. Wheldon TE, Kirk J, Finlay HM: Cyclical granulopoiesis in chronic granulocytic leukemia: A simulation study. *Blood* 43:379, 1974
188. Mackey MC, Glass L: Oscillations and chaos in physiological control systems. *Science* 197:287, 1977

189. Perry S, Moxley JH, Weiss GH, Zelen M: Studies of leukocyte kinetics by liquid scintillation counting in normal individuals and in patients with chronic myelogenous leukemia. *J Clin Invest* 45:1388, 1966
190. Zimmerman TS, Godwin H, Perry S: Studies of leukocyte kinetics in chronic lymphocytic leukemia. *Blood* 31:277, 1968
191. Mackey MC: A unified hypothesis for the origin of aplastic anemia and periodic haematopoiesis. *Blood* 51:941, 1978
192. Milton JG, Mackey MC: Periodic haematological diseases: Mystical entities or dynamical disorders? *J R Coll Phys Lond* 23:236, 1989
193. Mackey MC: Mathematical models of hematopoietic cell replication control, in Othmer HG, Adler FR, Lewis MA, Dallon JC (eds): *The Art of Mathematical Modeling: Case Studies in Ecology, Physiology and Biofluids*. New York, NY, Prentice Hall, 1966, p 149
194. Good PI: Alternative mechanisms for homeostatic regulation of mammalian cell populations. *J Theor Biol* 40:543, 1973
195. Grudinim MM, Klochko AV, Lukshin YV, Klochko EV: Study of the kinetics of the functioning of a population of haemopoietic stem cells using analogue modeling devices. *Biophysics* 23:343, 1978
196. Gruzdev GP, Monichev Y: Model of the regulation of the rate of multiplication of the stem cells of the bone marrow. *Biophysics* 20:308, 1975
197. Nazarenko VG: Influence of delay on auto-oscillations in cell populations. *Biophysics* 21:352, 1997
198. Nazarenko VG: Modification of the model of a cell population depressing its mitotic activity. *Biophysics* 23:337, 1978
199. Newton CM: Computer simulation of stem cell kinetics. *Bull Math Biophys* 27:275, 1965
200. Rotenberg M: Stability analysis of the two compartment model of cell proliferation. *J Theor Biol* 77:51, 1979
201. Rotenberg M: Theory of distributed quiescent state in the cell cycle. *J Theor Biol* 96:495, 1982
202. Rotenberg M: Transport theory for growing cell populations. *J Cell Biol* 103:181, 1983
203. Necas E, Hauser F: Simulation of CFU-S kinetics after irradiation. *Cell Tissue Kinet* 21:81, 1988
204. Necas E, Znojil V: Bone marrow response to single small doses of irradiation: Implications for stem cell functional organization. *Exp Hematol* 16:871, 1988
205. Necas E, Znojil V: Non-circadian rhythm in proliferation of haematopoietic stem cells. *Cell Tissue Kinet* 21:73, 1988
206. Maity A, McKenna WG, Muschel RJ: The molecular basis for cell cycle delays following ionizing radiation: A review. *Radiother Oncol* 31:1, 1994